Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.36 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30658533 | 1.00 | ALDH1A1 (0.45) | ALDH1A1TLR8MCHR1IRAK4KEAP1 | |
| Hydrochloric Acid SCHEMBL15534313 | 0.98 | ALDH1A1 (0.43) | ALDH1A1TLR8MCHR1IRAK4KEAP1 | |
| SCHEMBL23033967 | 0.85 | ALDH1A1 (0.42) | ALDH1A1KEAP1TDP1CYP3A4TSHR | |
| SCHEMBL1136306 | 0.84 | POLB (0.46) | ALDH1A1TLR8MCHR1IRAK4ALOX5AP | |
| SCHEMBL16338412 | 0.82 | ALDH1A1 (0.39) | ALDH1A1KEAP1MKNK1MKNK2 | |
| SCHEMBL16335648 | 0.82 | ALDH1A1 (0.39) | ALDH1A1KEAP1TDP1CYP3A4TSHR | |
| SCHEMBL16362682 | 0.82 | ALDH1A1 (0.39) | ALDH1A1KEAP1MKNK1MKNK2 | |
| SCHEMBL2313110 | 0.82 | ALDH1A1 (0.46) | ALDH1A1KEAP1TDP1CYP3A4TSHR | |
| SCHEMBL9070294 | 0.79 | ALDH1A1 (0.59) | ALDH1A1TLR8MCHR1IRAK4EP300 | |
| SCHEMBL7519140 | 0.79 | ALDH1A1 (0.44) | ALDH1A1TLR8MCHR1IRAK4EP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545654-B2 | MYC inhibitors and uses thereof | STEMSYNERGY THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4647127-A2 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | Exelixis, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-3743070-B1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | EXELIXIS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| CN-118056816-A | Pyrazole-3-ketone derivative, and preparation method and application thereof | 沈阳药科大学 | 2024-05-21 | — | — | CN | disclosed |
| EP-3939981-B1 | FUSED THIAZOLOPYRIMIDINE DERIVATIVES AS MNKS INHIBITORS | LIFEARC (GB) | 2024-04-03 | — | — | EP | disclosed |
| US-20240043414-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2024-02-08 | — | — | US | disclosed |
| EP-3792264-B1 | PYRROPYRIMIDINE COMPOUNDS AS MNKS INHIBITORS | LIFEARC (GB) | 2024-01-03 | — | — | EP | disclosed |
| CN-108368114-B | Pyrrolopyrimidine compounds as MNK inhibitors | 生命弧度公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-111757735-B | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2023-09-22 | — | — | CN | disclosed |
| US-20230150956-A1 | MYC INHIBITORS AND USES THEREOF | STEMSYNERGY THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20110015193-A1 | 1, 5-DIHYDRO-PYRAZOLO (3, 4-D) PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MUDULATORS FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| US-20100311749-A1 | 4-BENZOYL-1-SUBSTITUTED-PIPERAZIN-2-ONE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-12-09 | — | — | US | disclosed |
| EP-2212300-A1 | 4-BENZ0YL-1-SUBSTITUTED-PIPERAZIN-2-0NE DERIVATIVES AS P2X7 MODULATORS | Glaxo Group Limited (GB) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009053459-A1 | 4-BENZ0YL-1-SUBSTITUTED-PIPERAZIN-2-0NE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2009-04-30 | — | — | WO | disclosed |
| US-20060167014-A1 | Piperazine compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION | 2006-07-27 | — | — | US | disclosed |
| EP-1029851-B1 | PIPERAZINE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2005-04-20 | — | — | EP | disclosed |
| US-20030055064-A1 | Piperazine compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION | 2003-03-20 | — | — | US | disclosed |
| US-20030018034-A1 | Piperazine compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION | 2003-01-23 | — | — | US | disclosed |
| US-6455528-B1 | TUMOR NECROSIS FACTOR ANTAGONIST AND/OR INTERLEUKIN PROMOTER; ANTIALLERGENS, ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE TREATMENT | MITSUBISHI PHARMA CORPORATION (JP) | 2002-09-24 | — | — | US | disclosed |
| EP-1029851-A1 | PIPERAZINE COMPOUNDS AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150956-A1 | MYC INHIBITORS AND USES THEREOF | MYC, AURKA, AURKC | ALDH1A1 4332/4885TLR8 4402/4885MCHR1 3906/4885 |
| US-20110015193-A1 | 1, 5-DIHYDRO-PYRAZOLO (3, 4-D) PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MUDULATORS FOR THE TREATMENT OF CNS DISORDERS | PDE9A, PDE7A, PDE1C | ALDH1A1 127/4885TLR8 2435/4885MCHR1 1075/4885 |
| US-20030055064-A1 | Piperazine compounds and medicinal use thereof | TNF, IL5, CCR10 | ALDH1A1 710/4885TLR8 598/4885MCHR1 3504/4885 |
| US-20030018034-A1 | Piperazine compounds and medicinal use thereof | TNF, IL5, CCR10 | ALDH1A1 788/4885TLR8 435/4885MCHR1 3612/4885 |
| US-20060167014-A1 | Piperazine compounds and medicinal use thereof | TNF, CCR10, RELA | ALDH1A1 1148/4885TLR8 502/4885MCHR1 3196/4885 |
| US-20100311749-A1 | 4-BENZOYL-1-SUBSTITUTED-PIPERAZIN-2-ONE DERIVATIVES AS P2X7 MODULATORS | P2RX7, P2RX3, P2RX2 | ALDH1A1 3763/4885TLR8 230/4885MCHR1 227/4885 |
| US-12545654-B2 | MYC inhibitors and uses thereof | MYC, MYCBP, NR2E1 | ALDH1A1 4317/4885TLR8 4001/4885MCHR1 1853/4885 |
| US-20240043414-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, MAP3K6, MAP3K1 | ALDH1A1 3310/4885TLR8 2175/4885MCHR1 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.